Search clinical trials for: RNF43 mutation

Total 3261 results

Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Kazuhiko Yoshimatsu
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer

Colorectal Cancer

Japan
Novartis Pharmaceuticals

Active, not recruiting

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Melanoma | Pancreatic Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Cancer | Esophageal Squamous Cell Cancer | BRAF Mutant Colorectal Cancer | Cervical Squamous Cell Cancer | Lung Squamous Cell Cancer

Canada, Italy, Spain, Germany, Netherlands, United States, France
Redx Pharma Plc

Completed

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Colorectal Cancer

Spain, Korea, Republic of, United Kingdom, United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Gastrointestinal Cancer | CRC | Metastatic Pancreatic Ductal Adenocarcinoma | PDAC

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

First Human Trial of Targeting MDM2/MDMX PET Imaging

Nuclear Medicine | MDM2/MDMX Gene Mutation | Positron Emission Tomography Imaing
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
Massachusetts General Hospital

Not yet recruiting

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | NPM1 Mutation | KMT2A Rearrangement

United States
Novartis Pharmaceuticals

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (SPARKLE)

Sickle Cell Disease
Splice Bio

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene (POLARIS)

Stargardt Disease | Stargardt's Disease | STGD1 | Stargardt
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Assiut University

Not yet recruiting

Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients

EKLF Mutations in Beta Thalassemia Patients
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation (PRO-NEM1)

Neuroendocrine Tumors | MEN1 Mutation

France
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Quanta Therapeutics

Not yet recruiting

QTX3046 in Patients With KRAS G12D Mutations

Advanced Solid Tumor
Novartis Pharmaceuticals

Not yet recruiting

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (ASC4INDIA)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Centre Leon Berard

Not yet recruiting

Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO) (TACO)

Oral Squamous Cell Carcinomas

France
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
AstraZeneca

Not yet recruiting

Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. (Pangeia-2)

Metastatic Breast Cancer

Brazil
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Assistance Publique - Hôpitaux de Paris
Centre Leon Berard; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Not yet recruiting

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers (PGLEXPO2)

Environmental Exposure | SDH Gene Mutation | SDH-Related Familial Paraganglioma | SDHx-Related Syndromes

France
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study (PALBREAST)

Breast Cancer

Italy
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation

Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations

China
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
Radboud University Medical Center

Not yet recruiting

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis (STICRISC)

Peritoneal Carcinoma | Ovarian Carcinoma | Serous Tubal Intraepithelial Carcinoma | BRCA Mutation
Pauls Stradins Clinical University Hospital

Recruiting

Latvian Early Atherosclerosis Registry

Coronary Artery Disease | Atherosclerosis, Coronary

Latvia
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Solid Tumors
Tyligand Bioscience (Shanghai) Limited

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Malignant Neoplasm

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Washington University School of Medicine
Alzheimer's Association; Eisai Inc.

Not yet recruiting

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease (DIAN-TU)

Dementia | Alzheimer's Disease | Alzheimer's Disease, Familial

United States, Australia, United Kingdom
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
Acerand Therapeutics (Shanghai) Limited

Recruiting

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Solid Tumor, Adult

China
Centro di Riferimento Oncologico - Aviano

Recruiting

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)

Non Small Cell Lung Cancer Metastatic | ALK Gene Mutation

Italy
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
University College, London
Washington University School of Medicine; University of Washington; Alzheimer... and other collaborators

Not yet recruiting

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK (NIO-SILK)

Alzheimer Disease | Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) | Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) | Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Sensorion

Not yet recruiting

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Disorders | Deafness | Hearing Loss, Sensorineural | Congenital Deafness | DFNB9 | OTOF Gene Mutation

France
Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
University of Aarhus
Aarhus University Hospital

Recruiting

Circulating Tumor DNA in Peripheral T-cell Lymphomas (CIRCULATE)

Peripheral T-cell Lymphoma | NK/T-Cell Lymphoma

Denmark
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Shanghai Chest Hospital

Recruiting

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Carcinoma | Non-small Cell Lung Cancer

China
Case Comprehensive Cancer Center
National Institutes of Health (NIH); National Institute of Environmental Health...

Not yet recruiting

Linking Somatic Mutation Rate With Baseline Exposure in East Palestine

Somatic Mutation
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China

Search clinical trials for: RNF43 mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations